“Only buy something that you’d be perfectly happy to hold if the market shut down for 10 years.”
— Warren Buffett
A 10-year buy-and-hold investment in Amgen Inc (NASD: AMGN) produced a strong total return, helped by both share-price appreciation and the compounding effect of reinvested dividends. Using a starting investment date of 08/18/2016 and an ending date of 08/17/2026, a $10,000 position grew to $32,138.76, assuming dividends were reinvested.
That result translates to a total return of 221.36% and an average annual return of 12.38%. For long-term holders, the exercise highlights a central feature of Amgen stock as an investment case: returns have come not only from capital gains, but also from a meaningful and steadily reinvested income stream.
AMGN 10-Year Return Details
| Start date: | 08/18/2016 |
|
|||
| End date: | 08/17/2026 | ||||
| Start price/share: | $174.75 | ||||
| End price/share: | $419.38 | ||||
| Starting shares: | 57.22 | ||||
| Ending shares: | 76.63 | ||||
| Dividends reinvested/share: | $69.96 | ||||
| Total return: | 221.36% | ||||
| Average annual return: | 12.38% | ||||
| Starting investment: | $10,000.00 | ||||
| Ending investment: | $32,138.76 | ||||
The calculation implies that an investor who committed $10,000 to Amgen stock in August 2016 and held through August 2026 would have more than tripled the initial capital on a total-return basis. Put differently, the position added $22,138.76 of value over the decade, with dividends contributing both direct cash flow and incremental share accumulation through reinvestment.
[These numbers were computed with the Dividend Channel DRIP Returns Calculator.]
How Dividend Reinvestment Affected the Return
Dividend reinvestment was a meaningful part of the outcome. Over the 10-year period, Amgen Inc paid $69.96 per share in cumulative dividends. In this analysis, each dividend is assumed to be reinvested into additional shares at the closing price on the ex-dividend date.
That assumption increased the share count from 57.22 shares at the outset to 76.63 shares at the end of the period. The higher ending share count matters because each additional share participates in future dividends and any subsequent stock-price appreciation. That is the core mechanism behind compounding in a dividend reinvestment plan, or DRIP.
Key Takeaways
- Share-price appreciation drove a large portion of the gain, with the stock rising from $174.75 to $419.38.
- Reinvested dividends increased the number of shares owned over time.
- Total return provides a more complete measure than price return alone for a dividend-paying stock such as AMGN.
Current Yield and Yield on Cost
Based on the most recent annualized dividend rate of $10.08 per share, AMGN has a current yield of approximately 2.40%, using the ending share price shown above. That is the forward-looking income rate implied by the current dividend relative to the current stock price.
A separate concept is yield on cost, which measures the current annual dividend against the original purchase price rather than the current market price. Using the same $10.08 annualized dividend and the original purchase price of $174.75 per share, the yield on cost works out to about 5.77%.
What Is Yield on Cost?
Yield on cost is the current annual dividend divided by the original purchase price per share. It helps illustrate how a growing dividend can improve the income profile of a long-held position, even if the stock’s current market yield appears modest.
What This 10-Year AMGN Return Suggests
The decade-long result underscores why total-return analysis is important when evaluating a mature biotechnology company with a dividend. Amgen has historically combined characteristics that long-term shareholders often monitor closely: established commercial products, significant free-cash-flow generation, and a shareholder return framework that includes regular cash dividends. In a stock such as AMGN, long-run returns are often shaped by the interaction of earnings durability, capital allocation discipline, dividend growth, and valuation changes over time.
For any forward-looking assessment, the key questions are whether operating performance can support continued dividend payments and growth, whether the product portfolio can offset competitive pressures and patent-related headwinds, and whether the stock’s valuation leaves room for attractive future compounding. Those factors, rather than the historical return alone, will determine how Amgen stock performs over the next decade.
“Go for a business that any idiot can run – because sooner or later, any idiot probably is going to run it.” — Peter Lynch
